BIIB vs. AEP, NBIX, RGEN, PNW, CRSP, POR, DNLI, GILD, ARGX, and BNTX
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include American Electric Power (AEP), Neurocrine Biosciences (NBIX), Repligen (RGEN), Pinnacle West Capital (PNW), CRISPR Therapeutics (CRSP), Portland General Electric (POR), Denali Therapeutics (DNLI), Gilead Sciences (GILD), argenx (ARGX), and BioNTech (BNTX).
American Electric Power (NASDAQ:AEP) and Biogen (NASDAQ:BIIB) are both large-cap utilities companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Biogen received 1696 more outperform votes than American Electric Power when rated by MarketBeat users. Likewise, 72.02% of users gave Biogen an outperform vote while only 55.81% of users gave American Electric Power an outperform vote.
American Electric Power currently has a consensus target price of $87.08, suggesting a potential upside of 2.69%. Biogen has a consensus target price of $305.68, suggesting a potential upside of 41.30%. Given American Electric Power's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than American Electric Power.
American Electric Power has higher revenue and earnings than Biogen. American Electric Power is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 3 more articles in the media than American Electric Power. MarketBeat recorded 15 mentions for Biogen and 12 mentions for American Electric Power. Biogen's average media sentiment score of 0.56 beat American Electric Power's score of 0.32 indicating that American Electric Power is being referred to more favorably in the media.
American Electric Power has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.
75.2% of American Electric Power shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.1% of American Electric Power shares are owned by company insiders. Comparatively, 0.6% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Biogen has a net margin of 11.81% compared to Biogen's net margin of 11.64%. American Electric Power's return on equity of 14.91% beat Biogen's return on equity.
Summary
Biogen beats American Electric Power on 14 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools